Adebrelimab

monoclonal antibody

Identifier: CI-DRUG-00000817
Entity page: /drug/adebrelimab ↗
Edges: 213

Neighbours: 25 cancers1 genes10 trials
Drawn: 36 of 36 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Adebrelimab targets …TARGETS1 of 1
→ targets	CD274	—	INHIBITOR	—	1	Curated	chembl	graph →
Adebrelimab investigated for …INVESTIGATED_FOR15 of 17show all (up to 200)
→ investigated for	Lung Small Cell Carcinomasubtype	unknown

Adebrelimab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 47show all (up to 200)
→ investigated in trials for	Lung Small Cell Carcinomasubtype 19 trials (14 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Small Cell Carcinoma	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 14 trials (14 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 10 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 10 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Esophageal Squamous Cell Carcinoma 8 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Esophageal Squamous Cell Carcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Hepatocellular Carcinomasubtype 7 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hepatocellular Carcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Intrahepatic Cholangiocarcinoma 5 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Intrahepatic Cholangiocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Biliary Tract Neoplasm 5 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Biliary Tract Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasm 5 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Pancreatic Neoplasm 5 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Pancreatic Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastric Neoplasmcancer_family 4 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastric Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Squamous Cell Carcinomasubtype 4 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Squamous Cell Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Triple-Negative Breast Carcinoma 4 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Triple-Negative Breast Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Cervical Neoplasm 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Cervical Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Esophageal Neoplasm 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Esophageal Neoplasm	3	Observed	clinicaltrials	graph →

Adebrelimab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 47show all (up to 200)

→ investigated in trials for

Lung Small Cell Carcinomasubtype

19 trials (14 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Lung Small Cell Carcinoma

Observed

Adebrelimab studied in …STUDIED_INderived10 of 148show all (up to 200)
→ studied in	NCT06618664Phase 3 · recruiting A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02) · 148 trials list this drug (123 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07836543Phase 2 · not yet recruiting Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer · 148 trials list this drug (123 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07583550Phase 2 · recruiting Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer · 148 trials list this drug (123 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07827053Phase 2 · not yet recruiting Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer · 148 trials list this drug (123 active)	—	—	Pancreatic Ductal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07824882Phase 2 · not yet recruiting A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations · 148 trials list this drug (123 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07822542Phase 3 · not yet recruiting A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer · 148 trials list this drug (123 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06483282Phase 2 · recruiting A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer · 148 trials list this drug (123 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT06840002Phase 1/Phase 2 · recruiting A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer · 148 trials list this drug (123 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07811375Phase 2 · not yet recruiting Perioperative Adebrelimab for Locally Advanced Cervical Cancer · 148 trials list this drug (123 active)	—	—	Malignant Cervical Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07679360Phase 3 · recruiting A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer · 148 trials list this drug (123 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths